Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label

C A Aguilar-Salinas1, F J Gómez-Pérez, C Posadas-Romero

  • 1Instituto Nacional de la Nutrición 'Salvador Zubirán' de la SSA (Secretaría de Salud), Mexico City, Mexico. caas@aztlan.innsz.mx

Atherosclerosis
|September 22, 2000
PubMed